Analysts Set QuidelOrtho Corporation (NASDAQ:QDEL) PT at $14.88

QuidelOrtho Corporation (NASDAQ:QDEL) has earned a consensus recommendation of “Reduce” from the six research firms that are currently covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a sell recommendation and three have issued a hold recommendation on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $14.8750.

Several research firms have issued reports on QDEL. Zacks Research lowered shares of QuidelOrtho from a “hold” rating to a “strong sell” rating in a report on Tuesday, February 17th. UBS Group reaffirmed a “neutral” rating and set a $12.00 price target on shares of QuidelOrtho in a research report on Thursday, May 7th. Jefferies Financial Group downgraded QuidelOrtho from a “buy” rating to a “hold” rating and decreased their price target for the stock from $35.00 to $12.50 in a report on Thursday, May 7th. Weiss Ratings reiterated a “sell (e+)” rating on shares of QuidelOrtho in a report on Tuesday, April 21st. Finally, Wall Street Zen downgraded QuidelOrtho from a “buy” rating to a “hold” rating in a report on Sunday, April 12th.

QuidelOrtho Stock Up 3.1%

NASDAQ:QDEL opened at $14.57 on Tuesday. The firm’s 50 day simple moving average is $12.97 and its 200 day simple moving average is $21.15. The company has a debt-to-equity ratio of 1.33, a current ratio of 1.43 and a quick ratio of 0.80. QuidelOrtho has a one year low of $9.92 and a one year high of $35.58. The company has a market cap of $993.53 million, a PE ratio of -0.82 and a beta of 0.77.

QuidelOrtho (NASDAQ:QDEL) last posted its earnings results on Tuesday, May 5th. The company reported ($0.04) EPS for the quarter, missing the consensus estimate of $0.37 by ($0.41). QuidelOrtho had a positive return on equity of 4.25% and a negative net margin of 45.57%.The business had revenue of $619.80 million for the quarter, compared to analyst estimates of $665.23 million. During the same quarter in the prior year, the business earned $0.74 earnings per share. The firm’s quarterly revenue was down 10.5% on a year-over-year basis. QuidelOrtho has set its FY 2026 guidance at 1.800-2.000 EPS. On average, research analysts anticipate that QuidelOrtho will post 1.83 earnings per share for the current year.

Institutional Trading of QuidelOrtho

A number of large investors have recently bought and sold shares of QDEL. Aristotle Capital Boston LLC increased its stake in QuidelOrtho by 62.4% during the 3rd quarter. Aristotle Capital Boston LLC now owns 382,389 shares of the company’s stock valued at $11,261,000 after purchasing an additional 146,956 shares in the last quarter. American Century Companies Inc. increased its stake in QuidelOrtho by 10.4% during the 3rd quarter. American Century Companies Inc. now owns 2,115,557 shares of the company’s stock valued at $62,303,000 after purchasing an additional 199,909 shares in the last quarter. Public Sector Pension Investment Board increased its stake in QuidelOrtho by 17.2% during the 3rd quarter. Public Sector Pension Investment Board now owns 264,853 shares of the company’s stock valued at $7,800,000 after purchasing an additional 38,935 shares in the last quarter. Phocas Financial Corp. increased its stake in QuidelOrtho by 45.7% during the 4th quarter. Phocas Financial Corp. now owns 170,018 shares of the company’s stock valued at $4,856,000 after purchasing an additional 53,353 shares in the last quarter. Finally, Tejara Capital Ltd increased its stake in QuidelOrtho by 97.2% during the 4th quarter. Tejara Capital Ltd now owns 208,327 shares of the company’s stock valued at $5,950,000 after purchasing an additional 102,700 shares in the last quarter. 99.00% of the stock is currently owned by institutional investors and hedge funds.

About QuidelOrtho

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.